Avadel Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avadel Pharmaceuticals plc
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
- Drug Delivery
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Avadel Specialty Pharmaceuticals, LLC
- Éclat Pharmaceuticals, L.L.C.
- FSC Pediatrics, Inc.
- FSC Therapeutics, LLC
- FSC Laboratories, Inc.
- FSC Holdings, LLC
- Flamel Technologies